Navigation Links
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Date:8/27/2008

roviding the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS), which provides healthcare solutions that address the evolving needs of patients and societies. Focused on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

For more information

Additional information regarding G
'/>"/>

SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
2. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
3. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
4. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
5. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
6. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
10. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
11. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Scientific Corporation (NYSE: BSX ) today announced ... aggregate principal amount of its senior notes under the ... of $850 million of 4.50 percent notes due January ... 2020 and $300 million of 7.375 percent notes due ... net proceeds for general corporate purposes, including prepaying its ...
(Date:12/14/2009)... has completed the delivery of Brookfield Engineering’s Powder Flow Tester ... enclosure with a smaller footprint and more compact design. ... ... 2009 -- ThermoFab, a US-based thermoforming company, has completed the ... move from sheet metal to a plastic enclosure with a ...
(Date:12/11/2009)... December 10, 2009 miRagen Therapeutics, Inc., a ... developing innovative microRNA-based therapeutics for cardiovascular and muscle ... that microRNA-206 (miR-206) plays a crucial role in ... Lou Gehrig,s disease) and in neuromuscular synaptic regeneration ... December 11 issue of the journal Science ...
(Date:12/11/2009)... OSLO, December 11 Algeta ASA ... the first clinical center in the,US, the ... randomizing patients,in the phase III clinical study ... as hormone-refractory) prostate cancer,(CRPC) that has metastasized ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... change as a result of the Sarbanes-Oxley Act ... and companies to continually evaluate their financial controls ... to the technology requirements and information technology (IT) ... technology; however, it is difficult to envision compliance ...
... has an ancient and proud history of interstate sports ... Sometimes, like this past New Years Day, the rivalry ... Wolverines and marijuana have in common? They both get ... be fomenting another interstate rivalry. This one is of ...
... will support American Musical Supplys (AMS) expansion plans ... solutions. AMS , a supplier of musical ... next year and develop business-to-business sales channels using ... , ,AMS was driven to establish a ...
Other Biology Technology:Technology Implications of Sarbanes-Oxley 2Technology Implications of Sarbanes-Oxley 3For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 2For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 3For Now, Michigan Can Celebrate $150 Million Entrepreneurial VC Fund 4
(Date:12/13/2009)... Haven, Conn.A team led by Yale University researchers ... whole blood for the first time. Their findings, ... publication of Nature Nanotechnology , could dramatically ... cancer and other diseases. , The ... of Engineering & Applied Science, and Tarek Fahmy, ...
(Date:12/11/2009)... Malus orientalis species of wild apples that could be ... Middle East and Central Asia. A new study comparing ... varieties from Georgia and Armenia with previously collected varieties ... and establishes a core collection that will make ... research communities. , To identify and record the genetic ...
(Date:12/11/2009)... an associate professor of anthropology at the University of ... Kenya to understand how violence shapes the health of ... of her and her colleagues, research," Documenting the health ... northern Kenya: A conceptual framework," is currently published in ... , in collaboration with the British medical journal the ...
Breaking Biology News(10 mins):Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Understanding apples' ancestors 2UA-led study grapples with health effects of low-intensity warfare 2Yoga Can Ease Lower Back Pain 56417 1Yoga Can Ease Lower Back Pain 56417 2Yoga Can Ease Lower Back Pain 56417 3Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 1Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 2Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 3Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 4Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 5Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 6Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 7Reportlinker Adds Gastrointestinal Endoscopy Devices Report 56412 8K State Veterinarian Says Dog Owners Can Make Themselves Their Pets Healthier With Physical Activity Based on Dogs Specific Needs Interests 56409 1K State Veterinarian Says Dog Owners Can Make Themselves Their Pets Healthier With Physical Activity Based on Dogs Specific Needs Interests 56409 2K State Veterinarian Says Dog Owners Can Make Themselves Their Pets Healthier With Physical Activity Based on Dogs Specific Needs Interests 56409 3K State Veterinarian Says Dog Owners Can Make Themselves Their Pets Healthier With Physical Activity Based on Dogs Specific Needs Interests 56409 4
... advanced image, processing technology to the difficult challenge of rapidly ... ... 1 Aware, Inc. (Nasdaq:,AWRE), a global provider of imaging ... of software,development kits used to perform rapid autocapture and compliance ...
... living longer despite cellular defects, a discovery that is ... how doctors could one day limit or reverse genetic ... University of Colorado at Boulder study. , In the ... metabolic state of genetically engineered lab worms called C. ...
... p.m. to 7:30 p.m. , The New York Academy ... 40th Floor, New York, NY 10007 , The Malaria ... Public Health and The New York Academy of Sciences ... half-day symposium to highlight the latest research developments in ...
Other Biology News:Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture 2Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture 3CU-Boulder worm study sheds light on human aging, inherited diseases 2CU-Boulder worm study sheds light on human aging, inherited diseases 3Progress Against Malaria: Developments on the Horizon 2
B2-Microgloulin...
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... priced, full ring small animal imaging PET ... microPET R4 low retail price, it outperfoms ... count rate performance, energy resolution, timing resolution, ... small animal PET (Positron Emission Tomography) imaging ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: